{"title":"Current status and future perspectives of research on intra-articular drug delivery systems for osteoarthritis therapy","authors":"Mengru Wu , Zhihao Chen , Baoqin Song, Xiu Wang, Wanjun Liang","doi":"10.1016/j.actbio.2025.07.057","DOIUrl":null,"url":null,"abstract":"<div><div>Osteoarthritis (OA) is a degenerative joint disease and the leading cause of joint-related disability worldwide. In current clinical treatment approaches, drug therapy remains widely used, primarily through systemic administration of anti-inflammatory drugs and intra-articular injections. However, effective OA treatment remains challenging due to several barriers: the continuous flow of synovial fluid, the dense and negatively charged cartilage matrix, and the resulting poor drug accumulation at target sites. Moreover, rapid drug clearance from the synovial cavity, frequent dosing requirements, and increased risk of adverse effects further limit treatment efficacy. Recent advancements in intra-articular drug delivery systems, constructed from biological, organic, and inorganic materials, have demonstrated significant potential for OA treatment. Leveraging nanotechnology, these systems not only enhance targeted drug delivery to specific lesions but also enable controlled drug release at inflammatory sites through the optimization of nanocarrier design. This review explores the most innovative strategies for intra-articular drug delivery systems and the key challenges associated with this field. We discuss the development and research progress of emerging delivery technologies, including nanoparticles, liposomes, hydrogels, microspheres, and exosomes. Finally, we highlight the current limitations of intra-articular drug delivery systems and their prospects, aiming to provide valuable insights for further research and clinical translation.</div></div><div><h3>Statement of significance</h3><div>Osteoarthritis (OA) involves the progressive degradation of articular cartilage components, such as type II collagen and aggrecan, leading to chronic disability. Traditional treatments (systemic drugs, surgery) face limitations like poor targeting, short half-life, and invasiveness. While intra-articular injections enable localized delivery, rapid clearance, cartilage matrix barriers, and inadequate tissue penetration hinder efficacy. Recent advances in nanomaterials and drug delivery systems offer solutions. Stimulus-responsive nanocarriers enable precise targeting and controlled release in inflammatory microenvironments. Nanoparticles, liposomes, hydrogels, and microspheres enhance drug penetration and retention, overcoming rapid clearance. These innovations improve delivery efficiency and prolong the therapeutic effects, thereby advancing cartilage regeneration and personalized treatment. This review examines novel intra-articular delivery strategies to expedite the clinical translation of nanomaterial-based therapies.</div></div>","PeriodicalId":237,"journal":{"name":"Acta Biomaterialia","volume":"203 ","pages":"Pages 59-77"},"PeriodicalIF":9.6000,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Biomaterialia","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1742706125005562","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Osteoarthritis (OA) is a degenerative joint disease and the leading cause of joint-related disability worldwide. In current clinical treatment approaches, drug therapy remains widely used, primarily through systemic administration of anti-inflammatory drugs and intra-articular injections. However, effective OA treatment remains challenging due to several barriers: the continuous flow of synovial fluid, the dense and negatively charged cartilage matrix, and the resulting poor drug accumulation at target sites. Moreover, rapid drug clearance from the synovial cavity, frequent dosing requirements, and increased risk of adverse effects further limit treatment efficacy. Recent advancements in intra-articular drug delivery systems, constructed from biological, organic, and inorganic materials, have demonstrated significant potential for OA treatment. Leveraging nanotechnology, these systems not only enhance targeted drug delivery to specific lesions but also enable controlled drug release at inflammatory sites through the optimization of nanocarrier design. This review explores the most innovative strategies for intra-articular drug delivery systems and the key challenges associated with this field. We discuss the development and research progress of emerging delivery technologies, including nanoparticles, liposomes, hydrogels, microspheres, and exosomes. Finally, we highlight the current limitations of intra-articular drug delivery systems and their prospects, aiming to provide valuable insights for further research and clinical translation.
Statement of significance
Osteoarthritis (OA) involves the progressive degradation of articular cartilage components, such as type II collagen and aggrecan, leading to chronic disability. Traditional treatments (systemic drugs, surgery) face limitations like poor targeting, short half-life, and invasiveness. While intra-articular injections enable localized delivery, rapid clearance, cartilage matrix barriers, and inadequate tissue penetration hinder efficacy. Recent advances in nanomaterials and drug delivery systems offer solutions. Stimulus-responsive nanocarriers enable precise targeting and controlled release in inflammatory microenvironments. Nanoparticles, liposomes, hydrogels, and microspheres enhance drug penetration and retention, overcoming rapid clearance. These innovations improve delivery efficiency and prolong the therapeutic effects, thereby advancing cartilage regeneration and personalized treatment. This review examines novel intra-articular delivery strategies to expedite the clinical translation of nanomaterial-based therapies.
期刊介绍:
Acta Biomaterialia is a monthly peer-reviewed scientific journal published by Elsevier. The journal was established in January 2005. The editor-in-chief is W.R. Wagner (University of Pittsburgh). The journal covers research in biomaterials science, including the interrelationship of biomaterial structure and function from macroscale to nanoscale. Topical coverage includes biomedical and biocompatible materials.